Novo's Diabetes Combo May Find Home With General Practitioners
Despite FDA skepticism about fixed dosing, advisory committee says there are patients and providers who will benefit.
Despite FDA skepticism about fixed dosing, advisory committee says there are patients and providers who will benefit.